When you get vaccinated, your body makes antibodies to fight the virus. But how well do those defenders recognize and stop newer, different-looking variants? Researchers looked at blood samples from 100 people who were vaccinated and boosted to see what their antibodies could do in lab tests. They found that about 61 out of 100 samples could effectively neutralize the original Wuhan strain of the virus. However, the story changed with newer variants. Among those samples that worked against the original, only about 1 in 5 also showed the ability to cross-neutralize the Beta and Delta variants. Among that smaller group, about two-thirds could neutralize Omicron. The analysis also suggested that people who had been both vaccinated and previously infected showed stronger neutralizing responses than those who were just vaccinated and boosted. In a separate lab test looking at a potential risk called antibody-dependent enhancement (ADE), which in theory could make infection worse, it was observed in just 1 of the 100 samples. It's important to remember this is a retrospective look back at lab data from a single group of 100 people. The tests were done in dishes, not in people, so we don't know exactly how these findings translate to real-world protection against getting sick. The results highlight that our antibody defenses can be quite specific, which is why scientists continuously reassess vaccine strategies as the virus evolves.
Retrospective study finds 61% of vaccinated, boostered individuals neutralize Wuhan-Hu-1 SARS-CoV-2 variantHow well do vaccine antibodies fight different COVID variants?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Interpret in vitro neutralization data from this retrospective cohort cautiously regarding clinical protection.
A retrospective cohort study analyzed neutralizing antibody responses in serum samples from 100 vaccinated and boostered individuals. The study examined responses against SARS-CoV-2 variants including Wuhan-Hu-1, B.1.351, B.1.617, and Omicron, with secondary outcomes assessing cross-neutralization and antibody-dependent enhancement (ADE). No comparator group was reported, and the study design was observational.
Results showed 61 of 100 serum samples (61%) effectively neutralized the Wuhan-Hu-1 variant. Among these Wuhan-Hu-1 neutralizers, 20.6% demonstrated cross-neutralization against B.1.351 and B.1.617 variants. Among those cross-neutralizers, 66.6% were able to neutralize the Omicron variant. The study also reported that individuals with both vaccination and previous infection showed stronger neutralizing responses than those with vaccination and booster only, though no effect sizes or absolute numbers were provided for this comparison. ADE was observed in 1 of 100 samples (1%) in monocyte-derived macrophages.
Safety and tolerability data were not reported. The study's key limitation is its retrospective design, which precludes causal inference. The findings represent in vitro neutralization assays from a single cohort without clinical outcome data. The practice relevance is limited to underscoring the importance of continuously reassessing vaccine strategies as viral evolution unfolds, but these laboratory findings should not be directly extrapolated to clinical efficacy.
What this means for you:
Vaccine antibodies vary in their ability to fight different COVID variants in lab tests. More on SARS-CoV-2 infection
Clozapine Use Linked to Higher SARS-CoV-2 Infection Risk in Severe Mental Disorders
Clozapine users faced higher risk of severe COVID-19 in large study
A meta-analysis of 155,945 outpatients with severe mental disorders found that clozapine users had a higher rate of SARS-CoV-2 infection com…
A massive analysis of over 155,000 people found that those taking clozapine had higher rates of infection and worse outcomes from COVID-19.
Metformin, fluvoxamine, or ivermectin for non-hospitalized COVID-19 adults in a Phase 3 trial
Metformin Cuts Long Covid Risk by 40%
This randomized controlled trial in 1323 non-hospitalized adults with SARS-CoV-2 infection evaluated metformin, fluvoxamine, or ivermectin v…
A common diabetes pill taken early in Covid infection cuts the odds of developing long-term symptoms by 40%, offering new hope for millions.
Observational cohort study on SARS-CoV-2 evolution in immunocompromised patients
Long COVID Virus Changes Shape Inside Severely Ill Patients, Study Finds
This observational cohort study analyzed longitudinal SARS-CoV-2 genomes from 91 immunocompromised patients with COVID-19.
When the virus lingers too long in very sick patients, it changes in unpredictable ways, highlighting the need for stronger treatments.
Systematic review synthesizes immune and genetic factors in African SARS-CoV-2 populations
Why Africa saw milder COVID-19
This narrative synthesis reviews 40 studies from African settings regarding SARS-CoV-2 infection.
Africa saw milder COVID-19 because unique genes and immune defenses helped people fight the virus without getting severely sick.
View Original Abstract ↓
As the COVID-19 pandemic enters its sixth year, effective vaccination strategies remain a cornerstone, particularly given the limitations in access, timing, and efficacy of currently available antiviral therapies.
In this retrospective study, we analyzed neutralizing antibody responses in serum samples from 100 vaccinated and boostered individuals using standardized cell-culture and in vitro neutralization assays. Samples were tested against the original Wuhan-Hu-1 spike protein as well as major SARS-CoV-2 variants of concern (B.1.351, B.1.617, and B.1.1.529/Omicron). We also investigated the potential for antibody-dependent enhancement (ADE) in monocyte-derived macrophages.
Only 61% of serum samples effectively neutralized the Wuhan-Hu-1 variant; among these, 20.6% demonstrated cross-neutralization of both B.1.351 and B.1.617. Of those cross-neutralizers, 66.6% were also able to neutralize Omicron. Notably, individuals who had been both vaccinated and previously infected showed stronger neutralizing responses than those who were only vaccinated and boostered. ADE was observed in 1% of samples.
This retrospective analysis offers a valuable insight to contextualize immune responses in real-world settings, revealing how actual immunological outcomes diverged from early expectations; at least in our studied population, and underscores the importance of continuously reassessing vaccine strategies as viral evolution unfolds.
Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures
Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk
Related in Infectious Disease
FDA Approves Linezolid Injection for Gram-Positive Infections Including Pneumonia and Skin Infections
FDA approves new antibiotic injection for serious bacterial infections
The FDA approved linezolid injection for nosocomial pneumonia, community-acquired pneumonia, complicated skin infections, and vancomycin-res…
The FDA approved linezolid injection for treating serious infections like pneumonia and skin infections caused by certain bacteria, includin…
Intrawound vancomycin powder reduces postoperative infection risk (OR 0.59) in high-risk fracture fixation cases
Vancomycin Powder May Reduce Infections After High Risk Fractures
This meta-analysis of 3185 patients found that intrawound vancomycin powder significantly reduced postoperative infection rates (OR 0.59; 95…
A review of data suggests that using vancomycin powder in wounds may lower infection rates for patients with serious bone fractures.
Risk-adapted HLA delisting and imlifidase enable deceased-donor kidney transplantation for highly sensitized candidates
New guide helps transplant kidneys for hardest-to-match patients
This expert consensus provides a practical guideline for managing highly sensitized adult patients on the waitlist for deceased-donor kidney…
A new expert guide shows how to safely transplant kidneys into highly sensitized patients who have few options left.
Regenerative endodontic procedures may lead to unusual root morphology in immature teeth
Regenerative procedures can lead to unusual tooth root growth
This case report with literature review describes 2 immature teeth with pulp necrosis secondary to dens evaginatus treated with regenerative…
A new look at dental treatments shows that while some procedures save teeth, they can sometimes cause unexpected changes in how roots grow.
From Other Specialties
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.